Jun 24 |
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
|
Jun 5 |
InflaRx Hosts R&D Event Highlighting the Promise of INF904
|
May 21 |
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
|
May 8 |
InflaRx GAAP EPS of -€0.17 beats by €0.07, revenue of €36.03M beats by €35.89M
|
May 8 |
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 7 |
InflaRx Q1 2024 Earnings Preview
|
Apr 30 |
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
|
Apr 24 |
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
|